Surprisingly, this process does not rely on reactivating the BRAF-ERK pathway, which is the usual resistance mechanism. Using ...

To fight this, doctors often use drugs called BRAF inhibitors, such as vemurafenib, which can stop the cancer’s growth—at ...

BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK signaling cascade, a signal transduction pathway that transmits mitogenic ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

A research team led by Sheri Holmen, Ph.D., investigator at Huntsman Cancer Institute and professor in the Department of ...

but also sensitizes the tumors to specific inhibitors of pathway components. As we have reported, the BRAF and RAS mutant tumors are more sensitive to ERK pathway inhibition than the RAF/RAS wild type ...

Researchers at the University of California San Diego have uncovered a key mechanism underlying the treatment resistance of melanoma with the BRAF V600E mutation through pathways involved in focal ...

Vemurafenib (ZELBORAF, Hoffmann-La Roche Inc; Figure 1) is a first-in-class selective inhibitor of the BRAF serine-threonine kinase, FDA approved for the treatment of metastatic melanoma harboring ...

Surprisingly, this process does not rely on reactivating the BRAF-ERK pathway, which is the usual resistance mechanism. Using cutting-edge mass spectrometry-based phosphoproteomics and deep ...

Surprisingly, this process does not rely on reactivating the BRAF-ERK pathway, which is the usual resistance mechanism. Using cutting-edge mass spectrometry-based phosphoproteomics and deep ...